CpG1018
Phase 1Small molecule
CpG1018 is one of 4 small molecule programs targeting Immunity. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
4 competitors in Immunity
#DrugCompanyPhaseTrials
1Pneumococcal Conjugate Vaccine
NovartisPhase 2
Ervebo
AANRS, Emerging Infectious Diseases
Phase 3
CpG1018
NNYU Langone Health
Phase 1
BCG-Vaccine (SSI)
RRadboud University Medical Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CpG1018. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- NNYU Langone Health